Terapêutica disponível para a Doença hepática gordurosa não alcoólica e sua relação com a evolução do diabetes melito tipo 2: uma revisão de literatura / Available therapy for non-alcoholic fatty liver disease and its relationship with the evolution of type 2 diabetes mellitus: a literature review

Authors

  • Diego Handeri Hermes
  • Sersie Lessa Antunes Costa Almeida
  • Alice Faria Santos Fernandes
  • Diogo Ordones Delfraro
  • Helena Ribeiro de Oliveira
  • João Pedro Pereira
  • Lorena Galdino Teixeira
  • Matheus Victor Pereira
  • Natália de Azevedo Marques
  • Priscilla da Cunha Leal
  • João Paulo da Rocha Santos

DOI:

https://doi.org/10.34119/bjhrv3n4-364

Keywords:

Doença hepática gordurosa não alcoólica, Diabetes Mellitus Tipo II, Antidiabéticos, Perda de Peso.

Abstract

INTRODUÇÃO: A doença hepática gordurosa não alcoólica (DHGNA) é uma das principais causas de insuficiência hepática, hepatocarcinoma e transplante de fígado. Devido aos eventos que levam à sua evolução, torna-se essencial elucidar seus fatores de risco, a fim de instituir a prevenção de suas complicações. Um importante fator conhecido é o Diabetes Mellitus Tipo 2 (DM2) e, portanto, o objetivo deste artigo é discutir a correlação entre DHGNA e DM2 e seus tratamentos. RESULTADOS: A análise das informações demonstrou a diabetes como o principal fator de risco para o desenvolvimento da DHGNA e se estabeleceu como a melhor terapêutica disponível a perda de peso e o uso de tiazolidinedionas. DISCUSSÃO: A resistência insulínica e a DHGNA estão bidirecionalmente relacionadas. Dessa forma, a perda de peso e o uso de antidiabéticos são as principais formas encontradas para que haja um melhor prognóstico para o paciente. CONCLUSÃO: O diagnóstico precoce da DHGNA é imprescindível, objetivando estabelecer a melhor conduta clínica frente ao paciente. A detecção dos fatores de risco é indispensável para que se saiba indicar o tratamento ideal, entre os quais se destacam a perda de peso e o uso de antidiabéticos orais.

References

ANDRADE, G.C., et al. Non-alcoholic fatty liver disease (NAFLD) in different populations: A clinical and epidemiological study – sample of São José do Rio Preto. Rev Assoc Med Bras, v. 62, n 3. p. 218-226, 2016.

Bifari F; et al. Multiple target tissue effects of GLP-1 analogues on non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Pharmacological Research, v. 137, 2018.

DHARMALINGAM, M; YAMASANDHI, P.G. Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus. Indian J Endocrinol Metab, v. 22, n 3. p. 421–428, 2018.

European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. Obesity facts. 2016.

FERREIRA, V.S.G., et al. Frequency and risk factors associated with non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus. Arq Bras Endocrinol Metab, v. 54, n 4. p. 362-368, 2010.

GIESTAS, S. , et al. Liver Disease and Diabetes Mellitus – A Bi-Directional Relation. Revista Portuguesa de Diabetes. v.10, n 4. p. 158-166, 2015.

Grosso G.; et al. Mediterranean diet and cardiovascular risk factors: a systematic review. Critical Reviews in Food Science and Nutrition, v. 54, n.5, 2013.

Harrison S, et al. Non-Alcoholic Steatohepatitis Effect of Roux-en-Y Gastric Bypass Surgery. American Journal Gastroenterology, v. 101, n 2. p. 368-373, 2006

He, L., et al. Thiazolidinediones for nonalcoholic steatohepatitis: a meta-analysis of randomized clinical trials. Medicine, v. 95, n 42, 2016.

Jarvis H; et al. Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis of population-based observational studies. Public Library of Science Medicine, v. 17, n 4, 2020.

Kenneally, S., et al. Efficacy of dietary and physical activity intervention in non-alcoholic fatty liver disease: a systematic review. BMJ Open Gastroenterology, v. 4, n 1, 2017.

Koopman K.E.; et al. Hypercaloric diets with increased meal frequency, but not meal size, increase intrahepatic triglycerides: a randomized controlled trial. Journal of Hepatology, v.60, n.2, 2014.

Lallukka S Yki. Non-alcoholic fatty liver disease and risk of type 2 diabetes. Best practice and research. Clinical endocrinology and metabolism, v. 30, n 3, 2016.

Mantovani A, et al. Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: An updated systematic review of randomized controlled trials. Diabetes Metab DIABET-101142; No. of Pages 15, 2020.

Mantovani A, et al. Non-alcoholic fatty liver disease and risk of type 2 diabetes. Diabetes Journals, v. 41, p. 372-382, 2018

Marchisello, S., et al. Pathophysiological, Molecular and Therapeutic Issues of Nonalcoholic Fatty Liver Disease: An Overview. International Journal of Molecular Sciences, v. 20, n 8. p. 1948, 2019.

OTT-FONTES, P.R., et al. Comparison of the severity of non-alcoholic fatty liver disease in diabetic and non-diabetic obese patients. Rev. Col. Bras. Cir. v.47. Rio de Janeiro, 2020

Rahmanabadi A, et al. Oral ?-lipoic acid supplementation in patients with non-alcoholic fatty liver disease: effects on adipokines and liver histology features. Food Funct. 2019;10(8):4941-4952.

Raj H, et al. SGLT-2 inhibitors in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: A systematic review. World Journal of Diabetes, v. 10, n. 2, 2019.

Ratziu, V., et al. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. Gastroenterology, v. 135, n 1. p. 100-110, 2008.

Snowling N.J; et al. Effects of different modes of exercise training on glucose control and risk factors for complications in type 2 diabetic patients: a meta analysis. Diabetes Care, 2006.

Tang W., et al. Comparative efficacy of anti-diabetic agents on nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized and non-randomized studies. Diabetes/Metabolism Research and Reviews, v. 32, 2016.

Tilg, H.; Moschen, A. Weight loss: cornerstone in the treatment of non-alcoholic fatty liver disease. Minerva Gastroenterol e Dietologica, v. 56, n 2. p. 159-167, 2010.

Uusitupa, M. A. Lifestyle changes and cardiovascular risk reduction in diabetes.The lancet, v.4, n.11, 2016.

Velasco, J. V. R., et al. Extrahepatic complications of non-alcoholic fatty liver disease. Revista de Gastroenterología de México (English Edition), v. 84, n 4. p. 472-481, 2019.

Younossi, Z. M.; et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology, v. 64, n. 1, p. 73-84, 2016.

Zelber-Sagi, S., et al. Predictors for incidence and remission of NAFLD in the general population during a seven-year prospective follow-up. Journal of Hepatology, v. 56, n 5. p. 1145-51, 2012.

Published

2020-08-28

How to Cite

HERMES, D. H.; ALMEIDA, S. L. A. C.; FERNANDES, A. F. S.; DELFRARO, D. O.; OLIVEIRA, H. R. de; PEREIRA, J. P.; TEIXEIRA, L. G.; PEREIRA, M. V.; MARQUES, N. de A.; LEAL, P. da C.; SANTOS, J. P. da R. Terapêutica disponível para a Doença hepática gordurosa não alcoólica e sua relação com a evolução do diabetes melito tipo 2: uma revisão de literatura / Available therapy for non-alcoholic fatty liver disease and its relationship with the evolution of type 2 diabetes mellitus: a literature review. Brazilian Journal of Health Review, [S. l.], v. 3, n. 4, p. 11131–11145, 2020. DOI: 10.34119/bjhrv3n4-364. Disponível em: https://ojs.brazilianjournals.com.br/ojs/index.php/BJHR/article/view/15783. Acesso em: 28 mar. 2024.

Issue

Section

Original Papers